



Jennifer Elynn Yeh, MD PhD

Clinical Assistant Professor, Dermatology

CLINICAL OFFICE (PRIMARY)

- **Department of Dermatology**

450 Broadway St

Pavilion C 2nd Fl

Redwood City, CA 94063

Tel (650) 723-6316

Fax (650) 721-3464

ACADEMIC CONTACT INFORMATION

- **Administrative Contact**

Yvonne Nguyen - Administrative Associate III

Email ynguyen@stanford.edu

Tel 650-721-1774

Bio

BIO

Dr. Jennifer E. Yeh, M.D. Ph.D., is a Clinical Assistant Professor of Dermatology at Stanford University School of Medicine. Dr. Yeh graduated Phi Beta Kappa and Tau Beta Pi with a B.S. in chemical & biological engineering from the Massachusetts Institute of Technology. She received her M.D. and Ph.D. from Harvard Medical School, where she studied molecular modulators of the oncogenic transcription factor STAT3 and received the Ruth L. Kirschstein National Research Service Award from the National Cancer Institute. She completed her internship in internal medicine at Brigham and Women's Hospital followed by Dermatology residency in the Harvard Combined Dermatology Program where she served as Chief Resident during her final year.

Dr. Yeh co-directs a Dermatology-Rheumatology multidisciplinary clinic with a focus on autoimmune connective tissue diseases with Dr. Yashaar Chaichian (Rheumatology). Her clinical interests also include acne, eczema, psoriasis, and skin cancer. She has a special interest in medical education and serves as Co-Director of the Medical Dermatology curriculum for the Stanford Dermatology Residency Program. She also serves as the department's Wellbeing Director, championing initiatives to enhance professional fulfillment and reduce burnout.

CLINICAL FOCUS

- Dermatology
- Autoimmune Connective Tissue Diseases

ACADEMIC APPOINTMENTS

- Clinical Assistant Professor, Dermatology

ADMINISTRATIVE APPOINTMENTS

- Wellbeing Director, Department of Dermatology, Stanford WellMD/PhD Wellness Directors Council, (2022- present)
- Director of Residency Medical Dermatology Curriculum, Department of Dermatology, Stanford University, (2023- present)

HONORS AND AWARDS

- American Academy of Dermatology Academic Dermatology Leadership Program, American Academy of Dermatology (2024)

- American Academy of Dermatology Leadership Forum, American Academy of Dermatology (2023)
- Resident of Distinction Award, dermMentors (2020)
- New England Dermatological Society Case of the Year Award, New England Dermatological Society (2016)
- AACR Scholar-In-Training Award, San Antonio Breast Cancer Symposium (2014)
- Ruth L. Kirschstein National Research Service Award F30 Fellowship, NIH (2013-2017)
- Barry Goldwater Scholarship and Excellence in Education Award, Barry Goldwater Foundation (2008-2009)

BOARDS, ADVISORY COMMITTEES, PROFESSIONAL ORGANIZATIONS

- Member, Society for Investigative Dermatology (2023 - present)
- Member, Medical Dermatology Society (2022 - present)
- Member, Women's Dermatologic Society Diversity, Equity & Inclusion Committee (2022 - present)
- Member, Rheumatologic Dermatology Society, Resident & Fellow Committee (2021 - present)
- Member, American Academy of Dermatology (2021 - present)

PROFESSIONAL EDUCATION

- Board Certification: Dermatology, American Board of Dermatology (2021)
- Residency: Massachusetts General Hospital (2021) MA
- Chief Resident, Massachusetts General Hospital Harvard Combined Dermatology Residency (2021)
- Internship: Brigham and Women's Hospital Internal Medicine Residency (2018) MA
- Medical Education: Harvard Medical School (2017) MA
- MD, PhD, Harvard Medical School (2017)
- BS, Massachusetts Institute of Technology (2009)

LINKS

- Stanford Dermatology Subspecialty Clinics: https://med.stanford.edu/dermatology/patient_care/subspecialty.html

Publications

PUBLICATIONS

- **Causes and Clinical Presentation of Drug-Induced Dermatomyositis: A Systematic Review.** *JAMA dermatology*
Caravan, S., Lopez, C. M., Yeh, J. E.
2024
- **Livedoid vasculopathy.** *Dermatology online journal*
Leeolou, M. C., Rieger, K. E., Yeh, J. E.
2023; 29 (5)
- **Topical imiquimod in combination with brachytherapy for unresectable cutaneous melanoma scalp metastases.** *JAAD case reports*
Yeh, J. E., Wan, M. T., Alloo, A., Ibrahim, N., Buzurovic, I., Cohen, J. M., Ott, P. A., Laga, A. C., Devlin, P. M., Lin, J. Y.
2023; 31: 62-65
- **Topical imiquimod and cryotherapy in combination with systemic immunotherapy in unresectable stage IIIC melanoma.** *JAAD case reports*
Yeh, J. E., Wan, M. T., Alloo, A., Ibrahim, N., Ott, P. A., Buchbinder, E. I., Lin, J. Y.
2022; 27: 162-166
- **Small lymphocytic lymphoma presenting as chronic diffuse lip swelling** *Dermatology Online Journal*
Yeh, J. E., Lorenzo, M. E., Larocca, C., Fisher, D. C., Foreman, R. K.
2022; 28 (5): 4

- **Identifying inflammatory gene expression signatures for skin and soft tissue infections** *SKIN The Journal of Cutaneous Medicine*
Yeh, J., Pereira da Silva, M., Raff, A., Foreman, R.
2022; 6 (6): 534-538
- **Recognizing Multiple Diagnoses: Von Zumbusch Generalized Pustular Psoriasis Flare and Adverse Drug Effect** *SKIN The Journal of Cutaneous Medicine*
Yeh, J., Ward, A., Reynolds, R.
2022; 6 (4): 332-335
- **The antimicrobial drug pyrimethamine inhibits STAT3 transcriptional activity by targeting the enzyme dihydrofolate reductase.** *The Journal of biological chemistry*
Heppler, L. N., Attarha, S., Persaud, R., Brown, J. I., Wang, P., Petrova, B., Tošić, I., Burton, F. B., Flamand, Y., Walker, S. R., Yeh, J. E., Zubarev, R. A., Gaetani, et al
2021: 101531
- **Management of Cutaneous Immune-Related Adverse Events in Patients With Cancer Treated With Immune Checkpoint Inhibitors: A Systematic Review.** *JAMA oncology*
Nadelmann, E. R., Yeh, J. E., Chen, S. T.
2021
- **Targeting constitutively active STAT3 in chronic lymphocytic leukemia: A clinical trial of the STAT3 inhibitor pyrimethamine with pharmacodynamic analyses.** *American journal of hematology*
Brown, J. R., Walker, S. R., Heppler, L. N., Tyekucheva, S., Nelson, E. A., Klitgaard, J., Nicolais, M., Kroll, Y., Xiang, M., Yeh, J. E., Chaudhury, M., Giaccone, Z. T., Fernandes, et al
2021; 96 (4): E95-E98
- **Treatment of porokeratosis of Mibelli with combined use of topical fluorouracil and calcipotriene.** *JAAD case reports*
Yeh, J. E., Nazarian, R. M., Lorenzo, M. E.
2021; 9: 54-56
- **A Case of Fever and Erythema Nodosum-Like Lesions Leading to a New Diagnosis of Gamma-Delta T-Cell Lymphoma Complicated by Hemophagocytic Lymphohistiocytosis.** *Dermatopathology (Basel, Switzerland)*
Murphy, W. S., Yeh, J. E., Nazarian, R. M., Sohani, A. R., Kvedar, J., Kroshinsky, D.
2020; 6 (4): 266-270
- **Resolution of folliculitis decalvans with medical honey.** *Dermatology online journal*
Yeh, J. E., Hartman, R. I., Xu, J., Hoang, M., Yasuda, M. R.
2019; 25 (8)
- **The STAT3 Target Gene TNFRSF1A Modulates the NF- κ B Pathway in Breast Cancer Cells.** *Neoplasia (New York, N.Y.)*
Egusquiguire, S. P., Yeh, J. E., Walker, S. R., Liu, S., Frank, D. A.
2018; 20 (5): 489-498
- **Folliculin mutation-negative trichodiscomas in a patient with multiple endocrine neoplasia type I syndrome.** *Dermatology online journal*
Yeh, J. E., Tahan, S. R., Burgin, S.
2017; 23 (8)
- **Intractable pyoderma gangrenosum in a Crohn's disease patient on vedolizumab.** *JAAD case reports*
Yeh, J. E., Tsiaras, W. G.
2017; 3 (2): 110-112
- **Deregulation of SOCS5 suppresses dendritic cell function in chronic lymphocytic leukemia.** *Oncotarget*
Toniolo, P. A., Liu, S., Yeh, J. E., Ye, D. Q., Barbuto, J. A., Frank, D. A.
2016; 7 (29): 46301-46314
- **STAT3-Interacting Proteins as Modulators of Transcription Factor Function: Implications to Targeted Cancer Therapy.** *ChemMedChem*
Yeh, J. E., Frank, D. A.
2016; 11 (8): 795-801
- **Impact of the N-Terminal Domain of STAT3 in STAT3-Dependent Transcriptional Activity.** *Molecular and cellular biology*
Hu, T., Yeh, J. E., Pinello, L., Jacob, J., Chakravarthy, S., Yuan, G. C., Chopra, R., Frank, D. A.

2015; 35 (19): 3284-300

- **Inhibiting STAT5 by the BET bromodomain inhibitor JQ1 disrupts human dendritic cell maturation.** *Journal of immunology (Baltimore, Md. : 1950)*
Toniolo, P. A., Liu, S., Yeh, J. E., Moraes-Vieira, P. M., Walker, S. R., Vafaizadeh, V., Barbuto, J. A., Frank, D. A.
2015; 194 (7): 3180-90
- **Granulin, a novel STAT3-interacting protein, enhances STAT3 transcriptional function and correlates with poorer prognosis in breast cancer.** *Genes & cancer*
Yeh, J. E., Kreimer, S., Walker, S. R., Emori, M. M., Krystal, H., Richardson, A., Ivanov, A. R., Frank, D. A.
2015; 6 (3-4): 153-68
- **STAT3 Induction of miR-146b Forms a Feedback Loop to Inhibit the NF-kappa B to IL-6 Signaling Axis and STAT3-Driven Cancer Phenotypes** *SCIENCE SIGNALING*
Xiang, M., Birkbak, N. J., Vafaizadeh, V., Walker, S. R., Yeh, J. E., Liu, S., Kroll, Y., Boldin, M., Taganov, K., Groner, B., Richardson, A. L., Frank, D. A.
2014; 7 (310): ra11
- **Targeting transcription factors: promising new strategies for cancer therapy.** *Current opinion in oncology*
Yeh, J. E., Toniolo, P. A., Frank, D. A.
2013; 25 (6): 652-8
- **JAK2-STAT5 signaling: A novel mechanism of resistance to targeted PI3K/mTOR inhibition.** *JAK-STAT*
Yeh, J. E., Toniolo, P. A., Frank, D. A.
2013; 2 (4): e24635
- **STAT5 outcompetes STAT3 to regulate the expression of the oncogenic transcriptional modulator BCL6.** *Molecular and cellular biology*
Walker, S. R., Nelson, E. A., Yeh, J. E., Pinello, L., Yuan, G. C., Frank, D. A.
2013; 33 (15): 2879-90
- **Multi-genetic events collaboratively contribute to Pten-null leukaemia stem-cell formation** *NATURE*
Guo, W., Lasky, J. L., Chang, C., Mosessian, S., Lewis, X., Xiao, Y., Yeh, J. E., Chen, J. Y., Iruela-Arispe, M. L., Varella-Garcia, M., Wu, H.
2008; 453 (7194): 529-U7